2 results
Approved WMOCompleted
The primary objective is to evaluate the achievement of clinical response at Week 16 following a single IV re-induction dose of *6 mg/kg ustekinumab, compared with continuing regular SC q8w 90 mg ustekinumab administration, in participants with…
Approved WMOCompleted
Evaluate the long-term safety and effectiveness of two dose levels of orally administered BCX7353 in subjects with HAE